TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
OTC · CHNXF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ChitogenX Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ChitogenX Inc.’s next earnings report is currently expected on Dec 21, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ChitogenX Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate the efficacy of sports medicine surgical procedures through its research and development. Its developmental pipeline includes a range of specialized products: Ortho-R, a specific formulation designed for rotator cuff injuries; Ortho-M, a biopolymer addressing meniscus repair; Ortho-C, another biopolymer for the regeneration of articular cartilage; and Ortho-V, a biopolymer developed to facilitate the healing of osteoarthritis. Additionally, they are advancing ORTHO-T, a biopolymer formulation engineered for tendon healing and regeneration. Previously known as Ortho Regenerative Technologies Inc., the company adopted its current name, ChitogenX Inc., in September of 2022. Established in 2015, ChitogenX maintains its headquarters in Kirkland, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.020.0% vs estimate |
| $0.00 |
| Q3 2023 | Dec 28, 2022 | -$0.03-36.3% vs estimate | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
$0.00$0.00 (0.0%)
Actavia Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.5% below the high.
$0.00$0.00 (0.0%)
BioSyntech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Innovation Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
MedGen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Lift & Co. Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Nascent Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.85% below the high.
$0.00$0.00 (0.0%)
Avivagen Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.67% below the high.
